TX-OMNITRACS
9.9.2020 14:02:05 CEST | Business Wire | Press release
Omnitracs, LLC , a leader in SaaS-based fleet management and data analytics solutions and a pioneer in transportation technology, and SmartDrive, a leader in video-based safety and transportation intelligence, today announced that they have entered into a definitive agreement for Omnitracs to acquire SmartDrive. The combined company will bring together two transportation technology leaders to offer an industry-first converged, end-to-end platform that optimizes safety, driver productivity and workflow, as well as routing, dispatch and compliance.
Pervasive connectivity, advanced hardware, and the power of artificial intelligence (AI) and machine learning (ML) are just a few of the technology advancements that promise to unlock value and improve efficiency across all aspects of the $60B transportation technology industry. Unlocking that value in the highly fragmented fleet business, however, requires sufficient data and correlation. The new combined company will, for the first time, unite driving context with operational insight across hundreds of billions of data points to transform the experience for the driver, back office, and customer service alike.
“By integrating SmartDrive’s unparalleled transportation intelligence platform, video safety hardware and risk analysis service offering with the Omnitracs One platform, we can deliver a converged solution built on AI and ML that redefines the future of commercial transportation today. Real-time risk mitigation, streamlined data flows from the cab and vehicle sensors to dispatch and the back office, and a superior driver experience will be brought together to improve safety, efficiency and operational excellence,” said Ray Greer, Chief Executive Officer, Omnitracs. “We have long admired SmartDrive’s customer-centric approach to technology innovation and world class support and service. We look forward to welcoming the talented SmartDrive team to the Omnitracs family.”
There is no one-size-fits all solution for today’s fleets: the needs of oil and gas operations are very different from those of general freight – and both differ from local delivery and dozens of other transportation operations. Both Omnitracs and SmartDrive have built their businesses around providing enterprise-grade, flexible and adaptive solutions that can anticipate and address the distinct operating requirements of each fleet they serve. Together, their depth of experience across decades of partnerships will enable the combined company to uniquely support complexity at scale.
“We couldn’t be more excited about joining forces with Omnitracs and look forward to realizing and advancing the promise of convergence to the benefit of our shared customers,” stated Steve Mitgang, Chief Executive Officer, SmartDrive. “In Omnitracs, we have a like-minded company, seeing the power of data for innovation and solving material fleet and transportation industry challenges.”
The COVID-19 pandemic has underscored the significant role of commercial drivers, as the trucking sector has been instrumental to ensuring the availability of critical medical supplies and equipment, as well as essential consumer goods. Given the long-standing shortage of qualified drivers and high turnover rates, creating and sustaining a favorable driver experience (DX) is imperative to fleets’ success. However, recent transportation technology advancements have resulted in a proliferation of devices and sensors, the need for multiple cellular connections, siloed data streams that create redundancies, and other inefficiencies that stem from disparate onboard and back-office systems, all of which complicated the DX.
SmartDrive’s proven video-based safety program integrated with Omnitracs’ best-in-class driver workflow and complemented by the companies’ unmatched years of collective transportation intelligence present an opportunity to streamline and enhance DX. The combined company will deliver the most complete and intelligent DX with the right in-cab and back-office decision making, alerting, and driver coaching – a virtual co-pilot that will lead to significant safety, fuel efficiency, operational and financial gains for fleets.
“We’ve had great partnerships with both Omnitracs and SmartDrive over the years. We are excited to see these two companies come together,” said Chad England, Chief Executive Officer, C.R. England, Inc. “We are confident that the integration of offerings will create efficiencies for C.R. England. We congratulate both Omnitracs and SmartDrive on their new relationship and look forward to the future.”
Subject to customary closing conditions, including customary regulatory approval, the deal is expected to close later in calendar Q3 or Q4. Kirkland & Ellis LLP advised Omnitracs on the acquisition. PJT Partners is serving as exclusive financial advisor and Pillsbury Winthrop Shaw Pittman LLP is serving as legal counsel to SmartDrive.
About SmartDrive
SmartDrive Systems gives fleets and drivers unprecedented driving performance insight and analysis, helping save fuel, expenses and lives. Its video safety, predictive analytics, telematics, compliance and personalized performance program help fleets improve driving skills, lower operating costs and deliver significant ROI. With an easy-to-use managed service, fleets and drivers can access and self-manage driving performance anytime, anywhere. The company, which is ranked as one of the fastest growing companies by Deloitte’s Technology Fast 500™ for six consecutive years, has recorded nearly 25 billion miles and compiled the world’s largest storehouse of more than 300 million analyzed risky-driving events. SmartDrive Systems is based in San Diego, Calif., and employs over 725 people worldwide.
About Omnitracs, LLC
Omnitracs, LLC is the global pioneer of trucking solutions for all business models. Omnitracs’ more than 1,100 employees deliver software-as-a-service-based solutions to help over 14,000 customers manage nearly 1,100,000 assets in more than 70 countries. The company pioneered the use of commercial vehicle telematics 35 years ago and serves today as a powerhouse of innovative, intuitive technologies. Omnitracs transforms the transportation industry through technology and insight, featuring best-in-class solutions for compliance, safety and security, productivity, telematics and tracking, transportation management (TMS), planning and delivery, data and analytics, and professional services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005212/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom